| abstract |
Use use of the compounds of formula I, and pharmaceutically acceptable salts thereof (Formula I), in which R 1 represents hydrogen or cyclohexyϊ and R 2 represents hydrogen or alkyl C 1-6 provided that R 1 and R 2 do not both simultaneously represent hydrogen; in the treatment of diseases in which inhibition of IDO plays a therapeutic role, eg in the treatment of cancer. |